Shattuck Labs Inc is a biotechnology company focused on developing innovative immunotherapies to treat cancer and autoimmune diseases. The company was founded in 2016 and is headquartered in Austin, Texas, USA.
Shattuck Labs is pioneering the development of Agonist Redirected Checkpoint (ARC) therapies, which are designed to activate and redirect the immune system's natural response to cancer cells. Their approach combines the advantages of checkpoint inhibitors with tumor-targeting antibodies, aiming to enhance the effectiveness of cancer treatment while minimizing side effects.
The company's lead product candidate, known as SL-279252, is being investigated in clinical trials for the treatment of advanced solid tumors. SL-279252 is designed to target and activate the checkpoint protein OX40, which plays a critical role in stimulating the immune system's anti-tumor response.
Shattuck Labs boasts a team of experienced scientists, researchers, and executives dedicated to advancing their innovative immunotherapy platform. The company's work in developing ARC therapies has attracted attention from the scientific and medical communities, as well as potential investors looking for promising treatments in the field of cancer immunotherapy.